Lund University, Lund,
Professor Gesine Paul-Visse is a senior consultant neurologist and adjunct professor of Neurology at Lund University, Lund and Skåne University Hospital, Scania, Sweden.
She trained at the Charité – Universitätsmedizin Berlin, Germany, the United Medical and Dental Schools of Guy’s and St Thomas’ Hospitals (UMDS), London, UK and at the University of St Andrews, St Andrews, Scotland, UK. Attracted by Lund as a worldwide pioneering centre for neurotransplantation, Professor Paul-Visse joined the laboratory of Professor Patrik Brundin at Lund University in 2001 to work with cell therapies and neuroregeneration. Since 2011, she has led a preclinical research group “Translational Neurology” at Lund University, with a focus on understanding mechanisms of neurodegenerative disorders and identifying novel targets for neuroprotection.
Professor Paul-Visse works with patients with all neurological disorders but has a specialised profile in Parkinson’s disease. As such, she was head of the clinical movement disorder team (2016–2019) and serves on the board of the Swedish Movement Disorder Society (Swemodis), the Swedish Parkinson Academy, the Swedish Basal Ganglia Society (SWEBAGS), the Swedish Parkinson Registry (SWEPAR) and the Network of European CNS Transplantation and Restoration (NECTAR). She has also contributed to the national guidelines for Parkinson’s disease.
For more than a decade, Professor Paul-Visse has been a clinical investigator (or coordinating principal investigator) in several frontline clinical phase 1/2a trials that address the neurorestorative effect of growth factors (intracerebroventricular administration of platelet-derived growth factor and intracerebral administration of cerebral dopaminergic neurotrophic factor) in Parkinson’s disease.
She has also gained ample experience in cell transplantation by being a clinical investigator in the TransEuro trial, in which dopaminergic progenitors from foetal tissue were grafted into the putamen of patients with Parkinson’s disease using a similar stereotactic approach to the one planned for the STEM-PD trial.